Anti-Müllerian hormone predicts benefit of chemo + endocrine therapy in under-55s with breast cancer
Anti-Müllerian hormone (AMH) appears to predict the benefit of chemotherapy plus endocrine therapy (CET) versus ET alone in premenopausal women younger than 55 years with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with a recurrence score (RS) ≤25, according to a study published online July 24 in the Annals of Oncology.
A new study published in the Annals of Oncology predicts the effectiveness of chemotherapy plus endocrine therapy (CET) for premenopausal women under 55 years old with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer and a recurrence score of ≤25. Researchers from the Winship Cancer Institute at Emory University examined hormones linked to ovarian reserve to improve the prediction of CET benefit in 1,556 participants.
The research found that baseline estradiol, progesterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), Anti-Müllerian hormone (AMH), and inhibin B (INHB) levels did not predict CET benefit. However, when AMH was ≥10 pg/mL, there was a significant interaction with CET benefit for invasive disease-free survival (IDFS). IDFS was superior with CET versus endocrine therapy (ET) alone in 64% of women with AMH ≥10 pg/mL, while CET was not beneficial for the remaining 36% with low ovarian reserve (AMH <10 pg/mL).
Similar results were found for distant relapse-free survival. Ultrasensitive INHB levels also predicted CET benefit. Dr. Kevin Kalinsky, from the Winship Cancer Institute, stated that these results move us closer to precision medicine, as treatment decisions can be based on objective biological measurements of menopausal status rather than solely on age.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
